Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The Spike-E-M mosaic protein of SARS-CoV-2 is a recombinant antigen produced in *E. coli*, incorporating selected immunodominant epitopes from the virus's Spike, Envelope, and Membrane proteins. It is engineered for use in lab assays (such as ELISA) to detect antibodies against SARS-CoV-2[7]. It is not a naturally occurring, functional molecule in the virus or human host, nor is it considered a therapeutic or pharmacological target.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Spike-E-M mosaic protein of SARS-CoV-2 (SEM mosaic protein (unofficial; not an established abbreviation in the literature)).